MK-2894 is a highly potent and selective second generation EP4 antagonist.

MK-2048 is a potent inhibitor of HIV-1 integrase (IN) and IN mutant R263K with IC50 of 2.6 nM and 1.5 nM, respectively.

MK-204 is a potent, selective AKR1B10 inhibitor with IC50 of 80 nM, shows high selective (270-fold) over AKR1B1.

MK-1925 is a selective, orally active, brain-penetrant opioid receptor-like 1 (ORL1.

MK-1832 is a potent, selective Kv1.5 inhibitor with IC50 of 86 nM, exhibits improved selectivity for IKur over IKs (>3000-fold) compares with MK-0448 (70-fold), also exhibits an improved preclinical pharmacokinetic profile..

MK1 is a small molecule inducer of megakaryopoiesis (EC90=750 nM) that induces the differentiation of common myeloid progenitors (CMP) to megakaryocytes, does not adversely affect erythrocyte differentiation.

MK-0974(Telcagepant) is a highly potent, selective, and orally bioavailable CGRP receptor antagonist with Ki values of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors respectively; displays >1500-fold lower affinity for the canine and rat receptors

MK-0812 is chemokine receptor CCR-2 antagonist

MK-0731 is a potent, selective kinesin spindle protein (KSP) inhibitor with IC50 of 2.2 nM, cell EC50 of 5.3 nM.

MK-0674 is a potent, selective, reversible and orally active cathepsin K inhibitor with IC50 of 1 nM.

MK-0448 is a potent, specific I(Kur) current/Kv1.5 channel inhibitor with IC50 of 8.6 nM, potently inhibits IKur in human atrial myocytes with IC50 of 10.8 nM.

MK-0429 is a potent, selective, orally-active nonpeptide αvβ3 integrin inhibitor with IC50 of 0.08 nM in SPAV3 assay.

MK-0354 is a partial agonist of GPR109a receptor, for hGPR109a/ mGPR109a with EC50 of 1.65/1.08 μM, showed no activation of GPR109b.

MK-0249 is a novel potent, selective histamine H3 inverse agonist for the treatment of cognitive impairment with schizophrenia..

MJN-228 is a selective ligand for the lipid-binding protein nucleobindin 1 (NUCB1) with IC50 of 3.3 uM (blocks AEA-DA probe labeling of NUCB1).

Mizolastine is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions.

MIV-711 (MIV711, MV076159) is a potent, selective cathepsin K inhibitor with Ki of 0.98 nM, displays >1300-fold versus the other human cathepsins.

MIV-247 (MIV247) is a potent, selective, orally active inhibitor of cathepsin S with Ki of 2.1 nM (human cathepsin S).

miR544-IN-1 (SID 3712249) is a selective small molecule inhibitor of miR-544 biogenesis.

miR-21 inhibitor 37 is a novel inhibitor of miR-21 function with EC50 of 5.3 uM in HeLa-miR21-Luc assays, displays no inhibition of miR-122.

MIR17PTi is a novel LNA gapmeR antisense oligonucleotide (LNA-ASO), first-in-class inhibitor of pri-mir-17-92.

Minesapride (DSP-6952) is a novel potent, selective, orally active 5-HT4 receptor partial agonist with Ki of 50-100 nM for human 5-HT4a/4b/4c.

MIND-4 is a novel potent, selective, non-competitive SIRT2 deacetylase inhibitor with IC50 of 1.2 uM, Ki of 2.1 uM, and also is an inducer of the NRF2 pathway.

MIK665 (S-64315, MIK-665) is a novel potent, selective Mcl-1 inhibitor with potential pro-apoptotic and antineoplastic activities.

MIF-IN-3bb is a potent inhibitor of Migration inhibitory factor (MIF) tautomerase activity with Ki of 57 nM.

Midazolam (Dormicum.

MI-223 (NSC 320223) is a small molecule that specifically binds to Mcl-1 with Kd of 160 nM, inhibits HR DNA repair and sensitizes cancer cells to DNA replication agents.

MI-2-2 hydrochloride is a potent inhibitor of the menin-MLL interaction that binds to menin with low nanomolar affinity (Kd=22 nM).

MI-1481 (MI1481) is a highly potent inhibitor of the menin-MLL1 interaction with IC50 of 3.6 nM, 10-fold increase in inhibitory activity over MI-463 and MI-503.

MI 219 is a potent, specific MDM2-p53 inhibitor with Ki of 5 nM, >10,000-fold selective for MDM2 over MDMX.